There has been significant work in developing a form of IL-18 suitable for clinical application, including the development of a form of IL-18 that does not bind to IL-18DR and therefore elicits greater anti-tumor potency than wild-type IL-1842. This evidence concerns the gene IL18 and neoplasm.